Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02621151 · ClinicalTrials.gov registry record · Phase 2
Pembrolizumab (MK3475), Gemcitabine, and Concurrent Hypofractionated Radiation Therapy for Muscle-Invasive Urothelial Cancer of the Bladder
A Phase 2 study of Muscle-invasive Urothelial Cancer of the Bladder, sponsored by NYU Langone Health.
- Active
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 5
- Study locations
NCT02621151: Active Phase 2 study of Muscle-invasive Urothelial Cancer of the Bladder, sponsored by NYU Langone Health.
NCT02621151 is a Phase 2 study of Muscle-invasive Urothelial Cancer of the Bladder that is active but no longer recruiting, run by NYU Langone Health. The registered enrollment target is 60 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (55% lower). The trial reports 5 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02621151, a Phase 2 study of Muscle-invasive Urothelial Cancer of the Bladder, is active but no longer recruiting, sponsored by NYU Langone Health.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 5
- Study locations
Study Summary
This trial is to assess the efficacy of pembrolizumab (MK3475) added to concurrent radiation and gemcitabine in the management of patients with muscle-invasive urothelial cancer who are not candidates for or decline radical cystectomy.
Primary Outcome
Bladder-intact disease-free survival is defined as the time from initiation of protocol therapy until the first occurrence of muscle-invasive bladder cancer recurrence, regional pelvic recurrence, distant metastases, bladder cancer-related death, or cystectomy.
Conditions Studied
Interventions
- BIOLOGICAL Pembrolizumab
- RADIATION External Beam Radiation Therapy
- DRUG Gemcitabine
- PROCEDURE Transurethral Resection of Bladder Tumor
Study Locations (5)
New York
- NYU Perlmutter Cancer Center - New York
- Memorial Sloan Kettering - New York
Illinois
- University of Chicago - Chicago
Michigan
- University of Michigan Health System - Ann Arbor
North Carolina
- University of North Carolina - Chapel Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2016-08-11 |
| Est. Completion | 2025-12 |
| Phase | Phase 2 |
What the registry record for NCT02621151 still lists
NCT02621151 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (55% lower).
The record links to 1 condition, with Muscle-invasive Urothelial Cancer of the Bladder appearing as the primary indexed condition, and to 4 interventions - of which Pembrolizumab is the first listed.
NCT02621151 lists 5 locations in 4 states (New York, Illinois, Michigan).
Frequently Asked Questions
What is clinical trial NCT02621151 about?
NCT02621151 is a clinical study titled "Pembrolizumab (MK3475), Gemcitabine, and Concurrent Hypofractionated Radiation Therapy for Muscle-Invasive Urothelial Cancer of the Bladder". This trial is to assess the efficacy of pembrolizumab (MK3475) added to concurrent radiation and gemcitabine in the management of patients with muscle-invasive urothelial cancer who are not candidates for or decline radical cystectomy.
What is the current status of trial NCT02621151?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2016-08-11. Estimated completion is 2025-12.
What conditions does trial NCT02621151 study?
This clinical trial studies the following conditions: Muscle-invasive Urothelial Cancer of the Bladder.
What interventions are being tested in trial NCT02621151?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), External Beam Radiation Therapy (RADIATION), Gemcitabine (DRUG), Transurethral Resection of Bladder Tumor (PROCEDURE).
Who is sponsoring clinical trial NCT02621151?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02621151 being conducted?
This trial has 5 study locations across Illinois, Michigan, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02621151's enrollment target sits among peer trials
60 1027th of 2000 higher than 868 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI